Theralase Technologies Inc. (FRA:TTX)

Market Cap	24.60M
Revenue (ttm)	612.52K
Net Income (ttm)	-2.66M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0835
Previous Close	0.0815
Day's Range	0.0835 - 0.0835
52-Week Range	0.0815 - 0.2260
Beta	n/a
RSI	34.85
Earnings Date	Nov 28, 2025

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle...

• Industry: Electromedical and Electrotherapeutic Apparatus
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TTX

Financial Performance

In 2024, Theralase Technologies's revenue was 1.03 million, a decrease of -3.45% compared to the previous year's 1.07 million. Losses were -4.26 million, -6.89% less than in 2023.

Financial numbers in CAD